Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-2004 in autism spectrum disorder with irritability
NCT04895215Phase 2Completed
- Sponsor
- Vertero Therapeutics
- Start
- Aug 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules, Live Biotherapeutic Products
- Countries
- 3
01
Overview
A Phase 2 trial of AB-2004 in Autism Spectrum Disorder (ASD), sponsored by Vertero Therapeutics. Started Aug 2021; status: completed.
02
Drugs
AB-2004
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04895215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895215.